# Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)

> **NCT00882323** · PHASE2 · UNKNOWN · sponsor: **The Korean Society of Pediatric Hematology Oncology** · enrollment: 33 (estimated)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** Cyclophosphamide, Fludarabine, Thymoglobulin

## Key facts

- **NCT ID:** NCT00882323
- **Lead sponsor:** The Korean Society of Pediatric Hematology Oncology
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-11
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2012-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00882323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00882323, "Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00882323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*